References Camanni, F., Ghigo, E., & Arvat, E
Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon Receptor TriagonistObesity, NAFLD, and T2D Phase 2 Trial Results In this medfyle Two phase II studies showed that the triple agonist retatrutide is associated with significant weight loss in obese patients and substantial improvement in glycemia control and significant weight loss in patients with T2D
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C
[] Human PCa cells grown on DU-145 are shown to grow slower in the presence of epicatechin-3-O-gallate and theaflavins, while low-metastatic lymph node carcinoma of the prostate (LNCaP) and high-metastatic PC3 cells grow slower in the presence of difluoro analogs
Combination Approaches Future treatments might combine incretin agonists with other weight loss mechanisms like metabolism boosters, appetite suppressants working through non-incretin pathways, or fat absorption inhibitors
doi: 10.1016/j.trsl.2018.12.005 26 PetersonLSStelzerIATsaiASGhaemiMSHanXAndoKet al
